Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa, a biopharmaceutical company, has entered into a licensing agreement with Sanofi-Aventis providing the global healthcare company with access to BioWa's Potelligent technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity.
Subscribe to our email newsletter
Under the terms of the licensing agreement, BioWa grants Sanofi-Aventis non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through Potelligent technology for an undisclosed number of targets.
In return, BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other details of the agreement are not disclosed.
Jean-Marc Herbert, senior vice president of discovery research at Sanofi-Aventis, said: “By working with BioWa’s Potelligent technology, we will further improve the mechanism of action of our therapeutic antibodies and make them more potent and more effective against targeted diseases.”